Mirum Pharmaceuticals
The Key Account Manager (KAM) will develop and execute strategic account plans for priority centers and regional networks across Germany, building trusted partnerships with healthcare professionals and multidisciplinary care teams. The role focuses on improving awareness, access, and support for patients with rare liver diseases while ensuring compliance with legal and regulatory requirements.
Headquarters
Foster City, California, United States
Company Size
201-500 employees
Founded
2018
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing patient-inspired therapies for rare diseases where unmet medical need is greatest. The company has three approved medicines and a broad pipeline of investigational therapies spanning multiple rare disease areas, including cholestatic liver diseases and conditions such as Fibrodysplasia Ossificans Progressiva. Mirum combines deep rare disease expertise with regulatory strategy and patient access considerations to deliver meaningful treatments to small, high-need patient populations worldwide.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 hours ago
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Moderate Buy" by Brokerages
2 days ago
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Key Phase 3 Brelovitug Trial Milestones
3 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Mirum Pharmaceuticals.
Mirum Pharmaceuticals didn’t post a salary, so this is our estimate from similar listings.
4% above the average for this role
Mirum Pharmaceuticals at Leerink Conference: Strategic Growth Plans
14 hours ago